PDCD1 and neoplasm: Combination of BRAFi and anti‐mVEGFA antibody showed the strongest efficacy in association with PD‐1 blockade (herein after referred as “triple therapy”) and resulted in tumor size reduction of 85% after 12 day of short‐term treatment.